(NASDAQ: TNYA) Tenaya Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Tenaya Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TNYA's revenue for 2025 to be $2,440,003,965, with the lowest TNYA revenue forecast at $2,440,003,965, and the highest TNYA revenue forecast at $2,440,003,965. On average, 1 Wall Street analysts forecast TNYA's revenue for 2026 to be $3,253,338,620, with the lowest TNYA revenue forecast at $3,253,338,620, and the highest TNYA revenue forecast at $3,253,338,620.
In 2027, TNYA is forecast to generate $46,254,341,830 in revenue, with the lowest revenue forecast at $8,133,346,550 and the highest revenue forecast at $84,375,337,110.